Literature DB >> 25807231

Continuous improvement after multiple mesenchymal stem cell transplantations in a patient with complete spinal cord injury.

Danuta Jarocha1, Olga Milczarek, Anna Wedrychowicz, Stanislaw Kwiatkowski, Marcin Majka.   

Abstract

Interruption of spinal cord (SC) continuity leads to functional loss below the lesion level. The purpose of this study was to evaluate the safety and efficacy of bone marrow nucleated cell (BMNC) and multiple mesenchymal stem cell (MSC) transplantations in spinal cord injury (SCI). A patient with total SC interruption at the Th2-3 level underwent experimental therapy with BMNC and MSC transplantations followed with intensive neurorehabilitation treatment. At admission, 6 h after SCI, the patient was scored ASIA A, had a Th1 sensation level, paraplegia with sphincter palsy, and was without the ability to control trunk movement. Neurophysiology examination showed bilateral axonal damage to the motor and sensory neural fibers with no motor unit potentials or peripheral motor nerve conduction in the lower extremities. The standard therapy had been applied and had not produced any positive results. The patient was treated with autologous BMNCs injected intravenously (3.2×10(9)) and intrathecally (0.5×10(9)) 10 weeks after the SCI and with five rounds of MSCs every 3-4 months (1.3-3.65×10(7)) administered via lumbar puncture. Total number of transplanted MSC cells during the course of treatment was 1.54×10(8). There were no complications related to transplantations and no side effects related to the therapy during 2 years of treatment. The ASIA score improved from A to C/D (from 112 to 231 points). The sensation level expanded from Th1 to L3-4, and the patient's ability to control the body trunk was fully restored. Bladder filling sensation, bladder control, and anal sensation were also restored. Muscle strength in the left lower extremities improved from plegia to deep paresis (1 on the Lovett scale). The patient's ability to move lower extremities against gravity supported by the movements in quadriceps was restored. The patient gained the ability to stand in a standing frame and was able to walk with the support of hip and knee ortheses. Magnetic resonance imaging (MRI) revealed that at the Th2/Th3 level, where the hemorrhagic necrosis was initially observed, small tissue structures appeared. Our results suggest that repeated intrathecal infusions of MSCs might have the potential to produce clinically meaningful improvements for SCI patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25807231     DOI: 10.3727/096368915X687796

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  31 in total

1.  Clinical Study of NeuroRegen Scaffold Combined With Human Mesenchymal Stem Cells for the Repair of Chronic Complete Spinal Cord Injury.

Authors:  Yannan Zhao; Fengwu Tang; Zhifeng Xiao; Guang Han; Nuo Wang; Na Yin; Bing Chen; Xianfeng Jiang; Chen Yun; Wanjun Han; Changyu Zhao; Shixiang Cheng; Sai Zhang; Jianwu Dai
Journal:  Cell Transplant       Date:  2017-02-09       Impact factor: 4.064

2.  Defining recovery neurobiology of injured spinal cord by synthetic matrix-assisted hMSC implantation.

Authors:  Alexander E Ropper; Devang K Thakor; InBo Han; Dou Yu; Xiang Zeng; Jamie E Anderson; Zaid Aljuboori; Soo-Woo Kim; Hongjun Wang; Richard L Sidman; Ross D Zafonte; Yang D Teng
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

3.  Intrathecal transplantation of autologous adipose-derived mesenchymal stem cells for treating spinal cord injury: A human trial.

Authors:  Junseok W Hur; Tai-Hyoung Cho; Dong-Hyuk Park; Jang-Bo Lee; Jung-Yul Park; Yong-Gu Chung
Journal:  J Spinal Cord Med       Date:  2015-07-24       Impact factor: 1.985

4.  A Systematic Review of the Scientific Literature for Rehabilitation/Habilitation Among Individuals With Pediatric-Onset Spinal Cord Injury.

Authors:  Amanda McIntyre; Cristina Sadowsky; Andrea Behrman; Rebecca Martin; Marika Augutis; Caitlin Cassidy; Randal Betz; Per Ertzgaard; M J Mulcahey
Journal:  Top Spinal Cord Inj Rehabil       Date:  2022-04-12

5.  Multimodal Repair of Spinal Cord Injury With Mesenchymal Stem Cells: An Editorial Perspective.

Authors:  Sydney Brockie; Michael G Fehlings
Journal:  Neurospine       Date:  2022-09-30

Review 6.  Stem cell-based therapy for human diseases.

Authors:  Duc M Hoang; Phuong T Pham; Trung Q Bach; Anh T L Ngo; Quyen T Nguyen; Trang T K Phan; Giang H Nguyen; Phuong T T Le; Van T Hoang; Nicholas R Forsyth; Michael Heke; Liem Thanh Nguyen
Journal:  Signal Transduct Target Ther       Date:  2022-08-06

7.  A long-term anti-inflammation markedly alleviated high-fat diet-induced obesity by repeated administrations of overexpressing IL10 human umbilical cord-derived mesenchymal stromal cells.

Authors:  Liudi Wang; Tianyun Gao; Yu Li; Yuanyuan Xie; Sheng Zeng; Chenxu Tai; Yirui Feng; Pingping Shen; Bin Wang
Journal:  Stem Cell Res Ther       Date:  2022-06-17       Impact factor: 8.079

8.  Hair-Follicle-Associated Pluripotent (HAP) Stem Cells Encapsulated on Polyvinylidene Fluoride Membranes (PFM) Promote Functional Recovery from Spinal Cord Injury.

Authors:  Koya Obara; Natsuko Tohgi; Kyoumi Shirai; Sumiyuki Mii; Yuko Hamada; Nobuko Arakawa; Ryoichi Aki; Shree Ram Singh; Robert M Hoffman; Yasuyuki Amoh
Journal:  Stem Cell Rev Rep       Date:  2019-02       Impact factor: 5.739

9.  A Patch of Detachable Hybrid Microneedle Depot for Localized Delivery of Mesenchymal Stem Cells in Regeneration Therapy.

Authors:  KangJu Lee; Yumeng Xue; Junmin Lee; Han-Jun Kim; Yaowen Liu; Peyton Tebon; Einollah Sarikhani; Wujin Sun; Shiming Zhang; Reihaneh Haghniaz; Betül Çelebi-Saltik; Xingwu Zhou; Serge Ostrovidov; Samad Ahadian; Nureddin Ashammakhi; Mehmet R Dokmeci; Ali Khademhosseini
Journal:  Adv Funct Mater       Date:  2020-04-27       Impact factor: 18.808

Review 10.  Bone-Derived Modulators That Regulate Brain Function: Emerging Therapeutic Targets for Neurological Disorders.

Authors:  Hongzhen Chen; Dewei Shang; Yuguan Wen; Chao Liang
Journal:  Front Cell Dev Biol       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.